There are currently 63 active clinical trials seeking participants for Metastatic Cancer research studies. The states with the highest number of trials for Metastatic Cancer participants are California, Ohio, Michigan and Illinois.
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
NCT05335941
Recruiting
This is a Phase 2 open-label, single-arm trial for patients with MTAP-deficient advanced urothelial cancer who had received prior immunotherapy. This is a single site study at the University of Texas MD Anderson Cancer Center. This study will allow patients in second line of treatment for advanced urothelial ca or beyond. All patients must have been previously treated with immune checkpoint inhibitor (ICI) therapy as per current standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Urothelial Carcinoma, Metastatic Cancer
Register for Updates
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
NCT04085029
Recruiting
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Duke Cancer Institute Cary, Cary, North Carolina +4 locations
Conditions: Oligometastasis, Metastatic Cancer
Register for Updates
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045
Recruiting
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: SCRI HealthOne, Denver, Colorado +7 locations
Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor
Register for Updates
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
NCT05669482
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +11 locations
Conditions: KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
Register for Updates
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
NCT05831579
Recruiting
Spatially fractionated radiotherapy (SFRT or GRID) addresses some limitations of traditional stereotactic body radiation therapy by relying on beam collimation to create high-dose "peaks" and intervening low-dose "valleys" throughout the target volume. Standard palliative radiotherapy regimens provide limited durability of response, and there are challenges with delivery to large tumors or in previously irradiated fields. In this study, Proton GRID radiotherapy will be used to deliver three-frac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Unresectable Solid Tumor, Metastatic Cancer
Register for Updates
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237
Recruiting
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: University of Miami, Miami, Florida +26 locations
Conditions: Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
Register for Updates
Prospective Validation of a Points Score System Predicting 30-day Survival
NCT05100342
Recruiting
This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative treatments. Survival prediction score based on objective data including laboratory values, attendance to emergency room, and primary cancer origin will be assigned to each patient at time of enrollment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: IU Health West, Avon, Indiana +4 locations
Conditions: Metastatic Cancer
Register for Updates
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
NCT06090266
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: NEXT Austin, Austin, Texas +3 locations
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Cutaneous Melanoma, Non-small Cell Lung Cancer
Register for Updates
Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors
NCT04900818
Recruiting
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Stern Center for Cancer Clinical Trials and Research, Orange, California +20 locations
Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma
Register for Updates
A Study of the ApricityCare Program for Early Detection and Management of Treatment-related Adverse Events in Patients With Metastatic Cancer
NCT06693687
Recruiting
To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with metastatic cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Cancer
Register for Updates
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
NCT05877430
Recruiting
Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the unmet medical needs of low response rate and refractoriness to immune checkpoint inhibitors typically observed in this subject population by performing assessments of response, dose limiting toxicities,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of California, Irvine, Irvine, California +3 locations
Conditions: NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer
Register for Updates
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
NCT05475171
Recruiting
To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Cancer, Cervical Cancer
Register for Updates